Southampton General Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study in Adults With Geographic Atrophy

  NCT07606365· Phase 2· Sitala Bio LTD· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· BioNTech SE· Source

• Recruiting

  DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Phase 2/3· Cancer Research UK· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

  NCT07234942· Phase 1· Hoffmann-La Roche· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Recruiting

  DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

  NCT05770544· Phase 2/3· Cancer Research UK· Source

• Recruiting

  A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

  NCT07219966· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

  NCT07058077· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06948318· Phase 3· Takeda· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· BioNTech SE· Source

• Recruiting

  Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

  NCT06607458· Phase 2· Delcath Systems Inc.· Source

• Active, not recruiting

  UK ENcorafenib and BInimetinib Real-world Study in Melanoma

  NCT07022457· Pierre Fabre Ltd· Source

• Not yet recruiting

  Improving Diagnosis and Treatment for Patients With Rectal Cancer

  NCT07054047· Imperial College London· Source

• Recruiting

  A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979375· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979362· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· Phase 3· BeOne Medicines· Source

• Recruiting

  A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06722235· Phase 3· Takeda· Source

• Recruiting

  Ambroxol to Slow Progression in Parkinson Disease

  NCT05778617· Phase 3· University College, London· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· BioNTech SE· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

• Active, not recruiting

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

  NCT06460506· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

  NCT06988475· Phase 2/3· Cancer Research UK· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

  NCT07334301· Phase 1/2· University of Birmingham· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

  NCT06558279· Phase 3· argenx· Source

• Active, not recruiting

  STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

  NCT06571383· Phase 4· Novo Nordisk A/S· Source

• Recruiting

  Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Surgery

  NCT04103372· Imperial College London· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· UNICANCER· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

  NCT05635162· Phase 2· University College, London· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

  NCT06402838· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

  NCT06093672· Phase 3· Italfarmaco· Source

• Active, not recruiting

  A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

  NCT05568459· Regeneron Pharmaceuticals· Source

• Recruiting

  DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

  NCT05770037· Phase 2/3· Cancer Research UK· Source

• Recruiting

  A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.

  NCT07630545· Phase 1· Mission Therapeutics· Source

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

  NCT06073821· Phase 3· BeOne Medicines· Source

• Active, not recruiting

  A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

  NCT06072183· Phase 3· Pfizer· Source

• Recruiting

  DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

  NCT05770102· Phase 2/3· Cancer Research UK· Source

• Active, not recruiting

  Study in Patients With Decompensated Liver Cirrhosis

  NCT06380335· Resolution Therapeutics Limited· Source

Showing 50 of 91.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers14 recruiting
• Colorectal cancer7 recruiting
• Melanoma6 recruiting
• Lung cancer5 recruiting
• Heart failure4 recruiting
• Neuroblastoma4 recruiting
• Ovarian cancer4 recruiting
• Multiple myeloma3 recruiting
• Type 1 diabetes3 recruiting
• Bronchiectasis2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Parkinson disease2 recruiting
• Prostate cancer2 recruiting
• Sarcoma2 recruiting
• Thyroid cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Aortic stenosis1 recruiting
• Bladder cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Crohn's disease1 recruiting
• Familial hypercholesterolaemia1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Macular degeneration1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple system atrophy1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis

  NCT06478706· Phase 2· Enterprise Therapeutics Ltd· Source

• Recruiting

  A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

  NCT06439277· Phase 3· Eli Lilly and Company· Source

• Completed

  Cough Reduction in IPF With Nalbuphine ER

  NCT05964335· Phase 2· Trevi Therapeutics· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

  NCT05882357· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology

  NCT05470751· ConvaTec Inc.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Terminated

  Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

  NCT05605678· ApcinteX Ltd· Source

• Completed

  A Study of TAK-341 in Treatment of Multiple System Atrophy

  NCT05526391· Phase 2· Takeda· Source

• Completed

  A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

  NCT05083182· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

  NCT05185089· Phase 2· Nerre Therapeutics Ltd.· Source

• Terminated

  BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

  NCT05555251· Phase 1/2· BioInvent International AB· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Benralizumab Exacerbation Study

  NCT04102800· Phase 4· NHS Greater Glasgow and Clyde· Source

• Completed

  Short or Long Antibiotic Regimes in Orthopaedics

  NCT03806166· Oxford University Hospitals NHS Trust· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Gyroscope Therapeutics Limited· Source

• Completed

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· Phase 3· BeiGene· Source

• Completed

  A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

  NCT03631784· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

  NCT03648489· Phase 2· Imperial College London· Source

• Completed

  Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

  NCT03584165· Phase 3· NightstaRx Ltd, a Biogen Company· Source

• Completed

  Multiple Sclerosis-Simvastatin Trial 2

  NCT03387670· Phase 3· University College, London· Source

• Completed

  A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

  NCT03289962· Phase 1· Genentech, Inc.· Source

• Completed

  Repeatability and Reproducibility of Multiparametric MRI

  NCT03743272· Perspectum· Source

• Completed

  Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

  NCT02926196· Phase 3· Istituto Oncologico Veneto IRCCS· Source

• Completed

  Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

  NCT02719574· Phase 1/2· Forma Therapeutics, Inc.· Source

• Completed

  New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

  NCT02329080· Phase 2· International Extranodal Lymphoma Study Group (IELSG)· Source

• Completed

  Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours

  NCT01726374· Phase 3· Institute of Cancer Research, United Kingdom· Source

• Completed

  Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

  NCT00678327· Phase 3· University College, London· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Fatty liver disease (MASLD/MASH)25 works · 4 trials